Perrigo (PRGO) Other financing activities (2013 - 2026)
Perrigo's (PRGO) quarterly Other financing activities came in at -$500000.0 in Q1 2026, little changed year-on-year from -$500000.0 in Q1 2025, and up 90.91% on a QoQ basis from -$5.5 million in Q4 2025.
Perrigo (PRGO) Other financing activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other financing activities data on file, last reported at -$500000.0 in Q1 2026.
- On a quarterly basis, Other financing activities changed 0.0% year-over-year to -$500000.0 in Q1 2026; TTM through Mar 2026 was -$7.3 million, a 160.83% decrease from a year earlier, with the FY2025 full-year figure at -$7.3 million, down 1360.0% from the prior year.
- Other financing activities for Q1 2026 stood at -$500000.0, up from -$5.5 million in the prior quarter.
- Over the last five years, Other financing activities for PRGO reached as high as $18.0 million in Q4 2023 and fell as low as -$18.2 million in Q2 2025.
- Historically, Other financing activities has averaged -$964705.9 across 5 years, with a median of -$2.2 million in 2022.
- Across the five-year window, Other financing activities soared 500.0% in 2023 and plunged 787.5% in 2025, its largest moves.
- Year by year, Other financing activities stood at $3.0 million in 2022, then surged by 500.0% to $18.0 million in 2023, then sank by 95.56% to $800000.0 in 2024, then plunged by 787.5% to -$5.5 million in 2025, then soared by 90.91% to -$500000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were -$500000.0 in Q1 2026, -$5.5 million in Q4 2025, and $16.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -500,000.00 |
| Mar 28, 2026 | -500,000.00 |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 27, 2025 | 16.90 Mn |
| Sep 27, 2025 | 16.90 Mn |
| Jun 28, 2025 | -18.20 Mn |
| Jun 28, 2025 | -18.20 Mn |
| Mar 29, 2025 | -500,000.00 |
| Mar 29, 2025 | -500,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 28, 2024 | 14.00 Mn |
| Sep 28, 2024 | 14.00 Mn |
| Jun 29, 2024 | -2.30 Mn |
| Jun 29, 2024 | -2.30 Mn |
| Mar 30, 2024 | -13.00 Mn |
| Mar 30, 2024 | -13.00 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Dec 31, 2023 | 18.00 Mn |